Giovanni Guaraldi · Julian Falutz Chiara Mussi · Ana Rita Silva *Editors*

Managing the Older Adult Patient with HIV



Managing the Older Adult Patient with HIV

Giovanni Guaraldi • Julian Falutz Chiara Mussi • Ana Rita Silva Editors

Managing the Older Adult Patient with HIV



Editors

Giovanni Guaraldi Department of Medical and Surgical Sciences for Children & Adults University of Modena and Reggio Emilia Modena Italy

Julian Falutz
Director, Comprehensive
HIV & Aging Initiative
Chronic Viral Illness Service
Division of Infectious Diseases
Senior Physician, Division
of Geriatrics
McGill University Health Centre
Montreal
Canada

Chiara Mussi Centro di Valutazione e Ricerca Gerontologica University of Modena and Reggio Emilia Modena Italy

Ana Rita Silva
Department of Infectious
Diseases
Hospital Beatriz Ângelo
Loures
Portugal

ISBN 978-3-319-20130-6 ISBN DOI 10.1007/978-3-319-20131-3

ISBN 978-3-319-20131-3 (eBook)

Library of Congress Control Number: 2016937414

Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2016

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.

Printed on acid-free paper

Adis is a brand of Springer Nature Springer International Publishing AG Switzerland is part of Springer Science+Business Media (www.springer.com)

Editors

Julian Falutz, MD, FRCP(C) Director of Comprehensive HIV and Aging Initiative, Chronic Viral Illness Service, Division of Infectious Diseases and Geriatrics, McGill University Health Centre, Montreal, QC, Canada

Giovanni Guaraldi, MD Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy

Chiara Mussi, MD, PhD Centro di Valutazione e Ricerca Gerontologica, University of Modena and Reggio Emilia, Modena, Italy

Ana Rita Silva, MD Department of Infectious Diseases, Hospital Beatriz Ângelo, Loures, Lisbon, Portugal

Contributors

Thomas Brothers Dalhousie University in Halifax, Halifax, NS, Canada

Marta Calvo, MD, PhD Medical Affairs Manager for HIV and Hepatitis, Gilead Sciences, Madrid, Spain

André Fragoso Gomes, MD Department of Infectious Diseases, Hospital Garcia de Orta, Almada, Portugal

Esteban Martínez, MD, PhD Team Leader Consultant & Associate Professor of Medicine, Infectious Diseases Unit, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain

Contents

1	Introduction	1
2	Pathophysiology of HIV/AIDS Julian Falutz	7
3	HIV Associated Non-AIDS Conditions in Patients Aging with HIV	19
4	Comorbid Conditions and Older Adults with HIV	53
5	Frailty in HIVGiovanni Guaraldi and Thomas Brothers	67
6	Disability in HIV	89
7	Geriatric Syndromes	103
8	HIV Prevention and Screening in Older Adults	117
9	Multidimensional Geriatric Assessment in Older Patients with HIV	123

viii Contents

10	Antiretroviral Treatment in Older Patients Giovanni Guaraldi, André Fragoso Gomes, and Ana Rita Silva	129
11	HIV, Aging, and Polypharmacy Julian Falutz	181
12	Nutrition and Physical Exercise in Older Patients with HIV	189
13	Smoking Cessation in Patients with HIV	207
14	Self-management	217

Editor Biographies

Giovanni Guaraldi, **MD**, is Assistant Professor of Infectious Disease at University of Modena and Reggio Emilia, Italy, where he also completed his medical training. Dr Guaraldi undertook his residency at Liverpool School of Tropical Medicine, UK, and Jackson Memorial Hospital, USA.

Dr Guaraldi was awarded the Dean's Delegate Cooperation for development projects of Modena University. He has extensive experience in HIV in resource-limited countries and has coordinated the European, Africa, Caribbean, Pacific project CoBaSys (Community-Based System in HIV treatment) focused on antiretroviral access programs in sub-Saharan African countries.

In 2002 Dr Guaraldi started a liver and kidney transplant program for people with HIV at the multivisceral transplant center at Policlinico of Modena, Italy. Since the center opened, he has personally cared for approximately 80 patients with HIV who have received solid organ transplantation. Dr Guaraldi has led the Modena HIV Metabolic Clinic (MHMC) since 2000. This referral center cares for more than 4000 patients and offers a multidisciplinary team consisting of infectious disease physicians, nutritionists, occupational therapists, psychologists, cardiologists, nephrologists, endocrinologists, and plastic surgeons for the diagnosis and treatment of noninfectious comorbidities.

Dr Guaraldi has been the principal investigator in several studies generated by the MHMC, mainly focused on frailty and HIV-associated comorbidities. He has extensive experience in scientific publication, with more than 260

peer-reviewed papers, he is coeditor of *Journal of Antimicrobial Chemotherapy* and serves as reviewer for the major HIV journals and as a consultant for EMA. He supervises PhD students in the Experimental Medicine PhD course at Modena University.

Dr Guaraldi is a panel member of the European AIDS Clinical Society guidelines on prevention and management of HIV-associated comorbidities and has published widely on clinical aspects of HIV treatment and care.

Julian Falutz MD, **FRCP(C)**, is Assistant Professor of Medicine at McGill University and Associate Physician at the Montreal General Hospital Site of the McGill University Hospital Centre (MUHC), Canada. He is the director of the Comprehensive HIV and Aging Initiative in the Chronic Viral Illness Service and a Senior Physician in the Division of Geriatrics at the MUHC.

Dr Falutz attended McGill University School of Medicine, where he completed his residency in General Internal Medicine and received subspecialty training in both internal medicine and geriatrics. He has been actively involved in the clinical care of both HIV and geriatric patients at the MUHC for over 25 years. He is active as a clinical teacher at the undergraduate and graduate levels and was the director of the HIV elective program at the MUHC for 20 years.

His research in HIV has focused on the interaction of immunodeficiency, nutrition, and metabolic complications. He has initiated and participated in numerous studies on the management of HIV-related complications. He was the coprincipal investigator for the pivotal multinational studies investigating a novel growth hormone-releasing factor for the treatment of abdominal obesity in patients with HIV. The investigated drug has since been approved for use in both the USA and Canada. He is the Canadian coordinator for the REPRIEVE study, a multinational study of statins to prevent cardiovascular disease in low-risk treated HIV patients. He has initiated a program for the evaluation of patients aging with HIV and plays an active role in emerging studies evaluating frailty and comorbidities in patients aging with HIV.

Chiara Mussi, MD, PhD, is a Doctor in Medicine within the Modena HIV Metabolic Clinic at the University of Modena and Reggio Emilia, Italy. Dr Mussi earned her medical degree from the University of Modena and Reggio Emilia in 1995, and her graduation thesis centered on orthostatic hypotension in the elderly. In 1999 Dr Mussi specialized in geriatrics, and in 2004 she gained her PhD in biology and pathophysiology of aging, where her main research topic was cardiovascular autonomic changes in older patients. In 2008 she obtained a research grant from the University of Modena and Reggio Emilia to research syncope in the elderly. Dr Mussi has been a researcher and Chair of Geriatrics at the University of Modena and Reggio Emilia since 2009. She also works as an MD at the New S Agostino-Estense Civil Hospital in Baggiovara, Modena.

Dr Mussi has authored more than 100 peer-reviewed papers published in international and national journals, is an expert in multidimensional geriatric evaluation and geriatric syndromes, and has been a consultant in the Multidisciplinary Expert Working Group dedicated to HIV aging population issues since 2013 (sponsored by ViiV Healthcare).

Ana Rita Silva, MD, is an infectious disease specialist in the Department of Infectious Diseases at the Hospital Beatriz Ângelo, Portugal. She works within the infectious disease ward and is a consultant at the outpatient clinic. Dr Silva is currently undertaking her PhD in Clinical and Experimental Medicine at the University of Modena and Reggio Emilia, Italy, where Dr Giovanni Guaraldi and Dr Emília Valadas are her tutors.

Dr Silva attended the Coimbra School of Medicine (Faculdade de Medicina da Universidade de Coimbra) in Portugal and started her residency in Infectious Diseases in 2008. In 2009, after attending a 3-month internship at the Clinica Metabolica, Dr Silva helped to create the Metabolic Consult at the Hospital de Joaquim Urbano, Portugal. Since 2009 she has been involved in several projects in the area of HIV and aging, both in Portugal and with Dr Guaraldi in Italy, and has published several papers in this field. Dr Silva

Editor Biographies

xii

has also collaborated in the formation of residents and has participated as a lecturer in several courses, community actions, and congresses.

In 2013 she was awarded the certification in travel medicine by the International Society of Travel Medicine (ISTM) after taking the Certificate of Knowledge Examination. Throughout her career, Dr Silva has participated both as principal and coinvestigator in several studies on HIV and HIV/hepatitis C coinfection.

Contributor Biographies

Thomas Brothers is a medical student at Dalhousie University in Halifax, Nova Scotia, Canada.

Marta Calvo, MD, PhD, is the Spanish Medical Affairs manager for HIV and hepatitis at Gilead Sciences, Spain. She trained in medicine at the Universidad Autónoma de Madrid, Spain, and completed her residency in Internal Medicine at Hospital de Móstoles, Madrid, Spain, in 2006. Her academic training also includes a master's degree in AIDS, doctorate degree in medicine, and master's degree in design and analysis of clinical research from the Universidad de Barcelona, Spain.

Dr Calvo was responsible for a start-up hospital, Fundación Vicente Ferrer Hospital de Bathalapallí, dedicated to the care of patients with HIV/AIDS in rural India. She served as infectious disease specialist and medical scientist at the Infectious Disease Unit, Hospital Clínico de Barcelona-IDIBAPS, Spain, from 2007 to 2011, where she was also sub-investigator for several clinical trials. She has also completed a fellowship at the Infectious Disease Unit, University Hospital of Bonn, Germany, and served as an internist at the Emergency Department, Hospital de Fuenlabrada, Spain.

Dr Calvo has published over 20 peer-reviewed papers in international journals, written several book chapters, and spoken at numerous conferences, including the International AIDS Conference. She is fluent in Spanish, English, German, and Catalán.

André Fragoso Gomes, MD, is currently undertaking his residency in Infectious Diseases at the Department of Infectious Diseases of Hospital Garcia de Orta, Portugal, which he started in 2011. Dr Fragoso Gomes attended the Lisbon School of Medicine (Faculdade de Ciências Médicas, Universidade Nova de Lisboa).

Dr Fragoso Gomes has been actively involved in clinical care of patients with HIV at the Hospital Garcia de Orta, both within the wards and the outpatient clinic. He is particularly interested in metabolic disorders and other complications of HIV infection, especially the comorbidities that arise as patients age. Dr Fragoso Gomes worked at the Modena HIV Metabolic Clinic, Italy, for 3 months, where he develop his skills within the field and actively participated in ongoing clinical studies

Esteban Martínez, **MD**, **PhD**, is an Associate Professor of Medicine at the University of Barcelona and Senior Consultant in Infectious Diseases at the Hospital Clínic in Barcelona, Spain. Since 1996, he has devoted his time to outpatient care and the clinical research of HIV infection, and, in 2001, he took up a teaching role in infectious diseases at the University of Barcelona.

Dr Martínez was born in León, Spain, in 1963. He studied at the School of Medicine in Valladolid, Spain, from 1980 to 1986, and specialized in Internal Medicine at Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, from 1988 to 1992. In 1996 he achieved his PhD in neurological infections from the Autonomous University of Barcelona. His fields of interest span opportunistic infections, simplification of antiretroviral therapy, incidence and causes of death in HIV-infected persons receiving antiretroviral therapy, toxicity of antiretrovirals, and noninfectious complications in HIV-infected patients.

Dr Martínez is a member of the Scientific Board of the International Workshop on Adverse Drug Reactions and Co-morbidities in HIV and was the coauthor of the Spanish Guidelines on Antiretroviral Therapy from 2001, Spanish Guidelines for Metabolic Complications in HIV-Infected

Patients since 2003, Spanish Guidelines for Kidney (2010) and Bone (2013) Complications in HIV-Infected Patients, and Guidelines for the Prevention and Management of Non-infectious Co-morbidities in HIV (European AIDS Clinical Society) from 2007.

He is a member of Grupo de Estudio de SIDA (GESIDA), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), and European AIDS Clinical Society (EACS). He was elected as Regional (South Europe) Representative for EACS in 2012 for a 4-year period and has been a founding member of the International Symposium on Psychiatry and HIV (http://www.psiquiatria-vih.com/), held annually in Barcelona since 2007.

Dr Martínez has authored more than 200 papers and has led nine doctoral students. He has served as a reviewer for Dirección General de Investigación Científica y Técnica (Government of Spain), Agence Nationale de Recherche sur le Sida (France), UK Medical Research Council, South African Medical Research Council, Conselho Nacional de Desenvolvimento Científico e Tecnológico (Brazil), University of New South Wales, and University of Dublin. He has also served as a regular reviewer for major journals on medicine infectious diseases, chemotherapy, HIV/AIDS, endocrinology, bone, kidney, and circulation. He is an editorial board member of AIDS Research and Therapy, HIV Medicine, and Journal of Acquired Immune Deficiency Syndromes.

Preface

The 'graying' of the human immunodeficiency virus (HIV) epidemic is an established fact. Regardless of this evolving epidemiological context, no guidelines currently exist to offer a comprehensive view of the management of older patients with HIV.

This concise compendium addresses this gap by describing the aging trajectories of patients with HIV, by describing clinically meaningful end points, including comorbidities, multimorbidity, frailty, geriatric syndromes, and disability. Specific attention is given to the management of antiretroviral drugs in the context of polypharmacy in this special population.

In the context of the older patient with HIV, the model of HIV care is changing, and new strategies are needed to address the unmet healthcare needs of the aging patients. Best practices are presented together with the awareness that patient empowerment will remain at the core of innovative care models.

The authors of this book are infectious disease physicians and geriatricians, who are involved in the daily care of patients with HIV. We hope that this book will help not only doctors, but also allied care providers, including nurses, occupational therapists, social workers, psychologists, pharmacists,

xviii Preface

community leaders, families, and especially patients to better understand this changing paradigm and prepare for the future.

Ana Rita Silva Chiara Mussi Julian Falutz Giovanni Guaraldi

Abbreviations

AADL Advanced activities of daily living

AADL-CDI Advanced activities of daily living cognitive

disability index

AADL-DI Advanced activities of daily living disability

index

AADL-PDI Advanced activities of daily living physical dis-

ability index

ABC Abacavir

ACC American College of Cardiology

ADEs Adverse drug events
ADL Activities of daily living
AHA American Heart Association

AIDS Acquired immunodeficiency syndrome

AIN Anal intraepithelial neoplasia

ALT Alanine transaminase

AMPS Assessment of motor and process skills
ANI Asymptomatic neurocognitive impairment

ART Antiretroviral therapy

ARV Antiretroviral

AST Aspartate transaminase

AZT Azidothymidine BI Barthel index

BMD Bone mineral density BMI Body mass index

BNCS Brief Neurocognitive Screen

BUP Bupropion

CAM Confusion Assessment Method

Abbreviations

 $\mathbf{x}\mathbf{x}$

cART Combination antiretroviral therapy CGA Comprehensive geriatric assessment

CI Confidence interval

CIN Cervical intraepithelial neoplasia

CKD Chronic kidney disease

CKD-EPI Chronic Kidney Disease Epidemiology

Collaboration

CMV Cytomegalovirus

CNS Central nervous system

COPD Chronic obstructive pulmonary disease

CSF Cerebrospinal fluid CVD Cardiovascular disease DDI Drug-drug interactions

DSM-IIIR Diagnostic and Statistical Manual for Mental

Disorders Third Edition Revised

DXA Dual-energy X-ray absorptiometry

E/C/F/TAF Elvitegravir/cobicistat/emtricitabine/tenofovir

alafenamide

EACS European AIDS Clinical Society eGFR Estimated glomerular filtration rate

EI Entry inhibitor

EMA European Medicine Agency

ENDS Electronic nicotine delivery systems FDA Food and Drug Administration

FEV₁ Forced expiratory volume in 1 second

FRAX Fracture risk assessment tool

FVC Forced vital capacity

GALT Gut-associated lymphatic tissue GFR Glomerular filtration rate

GGT Gamma-glutamyl transphosphatase HAART Highly active antiretroviral therapy

HAD HIV-associated dementia HANA HIV-associated non-AIDS

HAND HIV-associated neurocognitive disorders

HbA1c Hemoglobin A1c HCV Hepatitis C virus

HDL High-density lipoprotein

HIV Human immunodeficiency virus

HIVAN HIV-associated nephropathy

HIV-VL HIV-viral load

HLA Human leukocyte antigen HPV Human papilloma virus

HR Hazard ratio

HRM High-risk morphology

IADL Instrumental activities of daily living ICKD Immune complex kidney disease

IDU Injecting drug users

IHDS The International HIV Dementia Scale

IL Interleukin

INI Integrase inhibitor

INSTI Integrase strand transfer inhibitor

IRP Immune risk phenotype

KS Kaposi's sarcoma

LDH Lactate dehydrogenase LDL Low-density lipoprotein

LGBT Lesbian, gay, bisexual, or transgender

LPS Lipopolysaccharide

MCI Mild cognitive impairment

MDRD Modification of Diet in Renal Disease

MHMC Modena HIV Metabolic Clinic

MM Multimorbidity

MNA Mini Nutritional Assessment
MND Mild neurocognitive disorder
MoCA Montreal cognitive assessment
MRI Magnetic resonance imaging
MSM Men who have sex with men

MVC Maraviroc

NHL Non-Hodgkin lymphoma NICM Noninfectious comorbidities

NK Natural killer

NNRTI Non-nucleoside reverse transcriptase inhibitor

NRT Nicotine replacement therapy

NRTI Nucleoside reverse transcriptase inhibitor NtRTI Nucleotide reverse transcriptase inhibitor

OTC Over-the-counter PI Protease inhibitor

xxii Abbreviations

PLWHA People living with HIV or AIDS

PPI Proton pump inhibitor PYFU Person-years of follow-up

QOL Quality of life

RDA Recommended daily allowance SCA Successful cognitive aging SGA Subjective Global Assessment STF Single-tablet formulations STR Single-tablet regimen T2DM Type II diabetes mellitus

TDF Tenofovir disoproxil fumarate

TMIG Tokyo Metropolitan Institute of Gerontology

Index

TNA Total number of activities
TNF Tumor necrosis factor

TSH Thyroid-stimulating hormone

VACS Veterans Administration Cohort Study

VAR Varenicline

Chapter 1 Introduction

Julian Falutz

Over 30 million people are infected with human immunodeficiency virus (HIV) today, more than 30 years after HIV/ acquired immunodeficiency syndrome (AIDS) was first described [1]. AIDS describes a set of usually fatal infectious and malignant diseases that occur in previously healthy individuals and are due to a progressively severe acquired immunodeficiency state. This state is due to infection with HIV, a unique retrovirus. Following exposure (via perinatal, bloodborne, or sexual vectors) to HIV, most people, overall, remain relatively well during a clinically latent phase that lasts on average 10 years. Most infected people may not be aware of being seropositive unless specifically tested for HIV. During the initial 15 year period of the epidemic antiretroviral therapy (ART) was unavailable. Most patients died of poor response to appropriate therapy of often concurrently occurring infectious and malignant complications, usually within 2-3 years of the initial AIDS complication [2]. However, during this period important advances were made and a deep

Director, Comprehensive HIV & Aging Initiative, Chronic Viral Illness Service, Division of Infectious Diseases, Senior Physician, Division of Geriatrics, McGill University Health Centre, Montreal, QC, Canada

e-mail: julian.falutz@mhc.mcgill.ca

J. Falutz, MD, FRCP(C)

understanding of HIV biology and the pathogenesis of AIDS occurred. This led to the progressive development of effective antiretroviral (ARV) drugs by the mid-1990s. These drugs, when used in specific combinations, referred to as highly active anti-retroviral therapy (HAART), transformed AIDS into a mostly manageable chronic disease. As a result few effectively treated patients still develop traditional AIDS-related complications [3].

Since the widespread introduction of HAART in the mid-1990s the survival of treated patients has increased significantly [4]. This has impacted on the mean age of the infected population. Currently, about 50% of infected persons in high-income countries are older than 50 years of age [5], with similar proportionate increases noted in non-industrialized countries. The age of 50 years has been used in HIV infection as a transition point separating older from younger patients, while recognizing that there is no specific biologic rationale for this precise age to represent older patients. Its use likely stems from the fact that during the first decade of the epidemic only a small minority (<10%) of affected patients in industrialized countries were older than 50 years of age [6], a proportion that has progressively increased to 50% at present [7].

Effective HIV risk prevention and education programs have significantly reduced new infection rates since HIV was identified as the etiologic agent of AIDS. However, new infections clearly still occur. The term 'long-term survivors' refers to patients infected early in the epidemic who either did not develop AIDS or survived those complications to benefit from the initial HAART regimens. Their improved survival is the main explanation for the overall increasing age of the majority of currently infected persons [5]. However, the age at the time of HIV seroconversion has also increased [8]. Older persons are at particular risk of exposure to HIV and other sexually transmitted infections for various reasons. Health care workers infrequently discuss sexual issues, including HIV, with older patients [9]; this is associated with a perception of low personal HIV risk among older persons. Also, the relative